Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to treat Type 2 diabetes and obesity. Recent research has expanded their potential applications ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

By Dr. Priyom Bose, Ph.D. Short-term increase in thyroid cancer diagnoses observed with GLP-1RA initiation, likely driven by ...